GHP Q3 2022

13 GHP Q3 2022 VIVO allows the treatment to be adjusted according to the patient’s individual pain perception, thus promising reduction of pain medication and lasting results. In chronic low back pain aVNS was able to produce in clinical trials a pain reduction of over 80% and a reduction of opioid intake by more than 90% over 6 weeks of therapy. Most impressively, the pain reduction was long-lasting for at least 3 months after therapy. For healthcare providers who are interested in learning more about or implementing VIVO, they can get in touch with AURIMOD by email or visiting the team at an event (go to to find out the events they will be attending). For individuals suffering from chronic pain who think VIVO might be able to help them, please speak to your doctor about the possibility of receiving aVNS therapy. Company: AURIMOD Contact: Stefan Kampusch, CEO Email: [email protected] Website: Founded in 2015, AURIMOD is a spin-off from the Medical University of Vienna and TU Wien which aims to help chronic pain patients to get back to their healthy and self-determined life. This vision motivates the team to do their best every day and to keep finding new, sustainable solutions that change lives for the better. Thus, they have developed VIVO, a smart wearable device that sets a new benchmark in pain management using auricular vagus nerve stimulation (aVNS) – Effective pain relief without medication. One in five people around the world are affected by chronic pain, with back pain being the most common. This pain is often treated using medication – with the risk of severe side effects and possible dependencies. At least 30% of these people living in the US and Europe are not receiving appropriate therapy, which has devastating effects on their quality of life. Auricular vagus nerve stimulation (aVNS) can be used to treat pain with a low side effect profile. AURIMOD’s minimally invasive and personalised chronic pain treatment - VIVO - is a CE marked neuromodulation device that is worn behind the ear and utilises aVNS. Its three small needle electrodes allow non-pharmacological treatment of chronic low back pain and migraines with a clinically proven and sustainable therapeutic effect. By reactivating the body’s own ways of reducing pain, VIVO offers a new alternative to pain management which comes with far fewer side effects and risks. It is the only solution on the market for non-pharmacological, personalized, and sustainable pain treatment for chronic low back pain patients. There are 12 cranial nerves in the human body, with the most important part of the so-called parasympathetic nervous system, a part of the autonomic (involuntary) nervous system, being the vagus nerve. This nerve regulates rest and recovery phases in the body as well as important bodily functions such as the inflammatory reaction, and it transmits information between organs and the brain. It runs from the brainstem to the organs in the abdomen and also to the auricle, where the nerve fibers of the vagus nerve are easily accessible. Chronic pain is often accompanied by (chronic) dysregulation in the autonomic nervous system. This is where aVNS comes in and modulates pain perception and pain processing through electrical impulses. Pain is different for everybody, so aVNS must be too. Most Innovative Chronic Pain Treatment Product 2022: VIVO Jul22140